Výsledky vyhledávání - "Maximino De Guzman Bello"

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

Autor: Yuriy Vinnyk, Marek Z. Wojtukiewicz, Yaroslav Shparyk, Xavier Pivot, Jin-Hee Ahn, Maximino De Guzman Bello, Sujeong Song, Vladimir Semiglazov, Zbigniew Nowecki, Sanjoy Chatterjee, Igor Bondarenko, Vladimir Moiseyenko, Seock-Ah Im, Ekaterina Trishkina, Jaeyun Lim, Tomasz Sarosiek, Mikhail Dvorkin

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 36(10)

Purpose This phase III study compared SB3, a trastuzumab (TRZ) biosimilar, with reference TRZ in patients with human epidermal growth factor receptor 2–positive early breast cancer in the neoadjuvant setting ( ClinicalTrials.gov identifier: NCT0214

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a617ccd5cfa3ffdde8e7de18d79122c9
https://pubmed.ncbi.nlm.nih.gov/29373094

Zobrazit plný text záznamu

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

Autor: Tomasz Sarosiek, Yaroslav Shparyk, Vladimir Moiseyenko, Seock Ah Im, Maximino De Guzman Bello, Xavier Pivot, Vladimir Semiglazov, Jae Yun Lim, Marek Z. Wojtukiewicz, M. Dvorkin, J.-H. Ahn, Y. Lee, Igor Bondarenko, Ekaterina Trishkina, Zbigniew Nowecki, Sanjoy Chatterjee

Publikováno v: European journal of cancer (Oxford, England : 1990). 93

Background The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and the trastuzumab reference product (TRZ) in terms of the breast pathologic complete response rate after neoadjuvant therapy in patients with early or locally advanc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49516f0b86f6bc234ba48ba45cbbea65
https://pubmed.ncbi.nlm.nih.gov/29680363

Zobrazit plný text záznamu

Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial

Publikováno v: Journal of Clinical Oncology. 37:6024-6024

6024 Background: In a previous global phase III trial (LUX-Head & Neck 1), second-line (2L) afatinib significantly improved PFS vs methotrexate (MTX) in pts with R/M HNSCC. Here, we compared efficacy/safety of 2L afatinib vs MTX in Asian pts with R/M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2ecc102f27631264e6ca34d61448d09c
https://doi.org/10.1200/jco.2019.37.15_suppl.6024

Zobrazit plný text záznamu

A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer

Autor: Seock-Ah Im, Maximino De Guzman Bello, Sanjay Chattopadhyay, Jae Yun Lim, Vladimir Semiglazov, Igor Bondarenko, Tomasz Sarosiek, Mikhail Dvorkin, Ekaterina Trishkina, Sujeong Song, Yaroslav Shparyk, Marek Z. Wojtukiewicz, Xavier Pivot, Vladimir Moiseyenko, Jin-Hee Ahn

Publikováno v: Journal of Clinical Oncology. 35:509-509

509 Background: SB3, a proposed biosimilar to the originator trastuzumab (TRZ), demonstrated similarity to its originator in terms of biological activities and pharmacokinetic (PK) equivalence. This study compared SB3 to TRZ in terms of efficacy, saf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::289a95b9132c24d0f4ef63153c50028d
https://doi.org/10.1200/jco.2017.35.15_suppl.509

Zobrazit plný text záznamu

One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment

Autor: Vladimir Semiglazov, Maximino De Guzman Bello, Xavier Pivot, S-A. Im, Marek Z. Wojtukiewicz, Jae Yun Lim, Yaroslav Shparyk, L. Younju, Zbigniew Nowecki, Sanjoy Chatterjee, Tomasz Sarosiek, J-H. Ahn, I. Bondarenko, Yuriy Vinnyk, Ekaterina Trishkina, Vladimir Moiseyenko, M. Dvorkin

Publikováno v: ResearcherID

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32710c319c83b36d3955dc96f3e0c284
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000411324000081&KeyUID=WOS:000411324000081

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání